Verdiva Bio, a London-based biotech, has raised £333.5m in a Series A round co-led by Forbion and General Atlantic. Launched in 2024, the company is developing next-generation weight loss therapies, including a first-in-class, once-weekly oral obesity treatment, aiming to rival Novo Nordisk's Ozempic.
The funding supports Verdiva's portfolio of innovative oral and injectable treatments, bolstered by its acquisition of global rights to a weight loss therapy from Sciwind Biosciences. Led by CEO Khurem Farooq, with a seasoned leadership team, Verdiva aims to improve patient access, affordability, and adherence, offering sustainable solutions for weight loss and maintenance. The company is positioned to address the growing global demand for advanced obesity treatments.
